Literature DB >> 2702756

Pyroglutamic acidemia in an adult patient.

M H Creer1, B W Lau, J D Jones, K M Chan.   

Abstract

Pyroglutamic acidemia, a rare metabolic disorder, usually appears in infancy. It is characterized by retardation, ataxia, hemolytic anemia, and chronic acidosis and is caused by a marked deficiency of glutathione synthetase (EC 6.3.2.3) activity. This disease is inherited as an autosomal recessive trait, but the clinical condition is also detected in heterozygotes. We report an unusual case of high-anion-gap metabolic acidosis in a 52-year-old woman who was admitted with neurological complaints and breathing problems but without the characteristic clinical features of congenital glutathione synthetase deficiency. The etiology of the acidosis could not be attributed to ketoacidosis, lactic acidosis, or ingestion of methanol, salicylate, or ethylene glycol. Analysis of the patient's plasma and urine for organic acids revealed the presence of high concentrations of pyroglutamate (5-oxoproline), which remained high throughout her hospitalization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702756

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Atypical pyroglutamic aciduria: possible role of paracetamol.

Authors:  J J Pitt; G K Brown; V Clift; J Christodoulou
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine.

Authors:  Gregory L Hundemer; Andrew Z Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

3.  Refractory metabolic acidosis in patients with sepsis following hemiarthroplasty for femoral neck fracture: a causative role for paracetamol and flucloxacillin?

Authors:  Halima Amer; Frances Dockery; Nicholas Barrett; Marc George; Karolina Witek; Jeremy Stanton; Diane Back
Journal:  BMJ Case Rep       Date:  2011-07-20

4.  Lesson of the month 1: A rare adverse reaction between flucloxacillin and paracetamol.

Authors:  William Osborne; Aneeka Chavda; George Katritsis; Jon S Friedland
Journal:  Clin Med (Lond)       Date:  2019-03       Impact factor: 2.659

5.  Paracetamol prevents hyperglycinemia in vervet monkeys treated with valproate.

Authors:  Jacques Viljoen; Jakobus J Bergh; Lodewyk J Mienie; Hercullas F Kotze; Gisella Terre'Blanche
Journal:  Metab Brain Dis       Date:  2012-02-17       Impact factor: 3.584

6.  Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid.

Authors:  Barry A Mizock; Stanislav Belyaev; Carter Mecher
Journal:  Intensive Care Med       Date:  2003-12-19       Impact factor: 17.440

Review 7.  Acetaminophen toxicity and 5-oxoproline (pyroglutamic acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle.

Authors:  Michael Emmett
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 8.237

8.  Profound metabolic acidosis and oxoprolinuria in an adult.

Authors:  Michael J Hodgman; James F Horn; Christine M Stork; Jeanna M Marraffa; Michael G Holland; Richard Cantor; Patti M Carmel
Journal:  J Med Toxicol       Date:  2007-09

9.  Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use.

Authors:  Anis Zand Irani; Ahmed Almuwais; Holly Gibbons
Journal:  BMJ Case Rep       Date:  2020-04-08

10.  The Impact of Pyroglutamate: Sulfolobus acidocaldarius Has a Growth Advantage over Saccharolobus solfataricus in Glutamate-Containing Media.

Authors:  Anna M Vetter; Julia Helmecke; Dietmar Schomburg; Meina Neumann-Schaal
Journal:  Archaea       Date:  2019-04-24       Impact factor: 3.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.